argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Tuesday, April 11, 2017 1 min read

Key Takeaway: argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Full Press Release Details

argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients.